Quotient Sciences has acquired Arcinova, a U.K.-based CDMO. Arcinova has 160 employees, and provides drug substance, drug product and bioanalysis services to more than 200 pharma/biopharma customers worldwide.
 
The acquisition expands Quotient’s services with drug substance, drug product and clinical testing capabilities, along with the 12-month drug development timeline delivered by Quotient’s flagship platform Translational Pharmaceutics.
 
“I’d like to congratulate the Arcinova team on building an exciting business, and I am thrilled to be joining forces. Both businesses are similar in culture and aspire to help customers accelerate molecules from candidate selection through development and on to commercial launch,” said Mark Egerton, Ph.D., CEO of Quotient Sciences. “I’d also like to take this moment to thank our private equity partner, Permira, for supporting our ambitious growth plans.”
 
Professor Ian Shott, CBE, co-founder and executive chairman of Arcinova, said, “Since inception, we set out to build a unique organization that accelerates the development of new medicines for patients in need. We are delighted to move on to the next stage with Quotient as the perfect partner for Arcinova. Deep science, agility, flexibility and the drive for customer service excellence are the cornerstones of both businesses. I look forward to working with the Quotient team and Permira to deliver even greater value for our customers.”
 
As part of the deal, Arcinova’s minority equity partner, BGF, will exit the business.